---
title: Provider Products & Services - Beta-Lactam | InsightRX
description: Products and services for commonly used beta-lactam agents, such as cefepime, meropenem, and piperacillin
---
[](https://www.insight-rx.com/?hsLang=en)
- For Providers
- Solutions
- [MIPD for Providers Explore our full solution for Bayesian model-informed dosing](https://www.insight-rx.com/mipd?hsLang=en)
- [Future of Pharmacy Learn what's next for AI in health tech, and why architecture matters](https://www.insight-rx.com/future?hsLang=en)
- Products
- [InsightRX Nova Bayesian dosing (MIPD) app for bedside clinical decision support](https://www.insight-rx.com/provider/nova?hsLang=en)
- [InsightRX Apollo Real-time clinical analytics to measure outcomes](https://www.insight-rx.com/provider/apollo?hsLang=en)
- [Drug Modules Available medications for precision dosing apps](https://www.insight-rx.com/provider/drug-modules?hsLang=en)
- [For Life Sciences](https://www.insight-rx.com/life-sciences?hsLang=en)
- Overview
- [InsightRX for Life Sciences Explore our solution for biopharma and clinical trial use](https://www.insight-rx.com/life-sciences?hsLang=en)
- Products
- [Nova for Life Sciences Precision dosing app for clinical trial use](https://www.insight-rx.com/life-sciences/nova?hsLang=en)
- [Astra for Life Sciences AI-native environment for PK/PD modeling and simulation](https://www.insight-rx.com/life-sciences/astra?hsLang=en)
- Platform
- [Continuous Learning Patented process for model retraining and improvement](https://www.insight-rx.com/platform/continuous-learning?hsLang=en)
- [Integrations Platform interoperability setup with EHRs, EDCs, and more](https://www.insight-rx.com/platform/integrations?hsLang=en)
- [Security & Regulatory Standards for product development and release](https://www.insight-rx.com/platform/security-regulatory?hsLang=en)
- [Success & Support Pharmacist-led training, onboarding, and education](https://www.insight-rx.com/platform/support?hsLang=en)
- Resources
- Science
- [Data Science Explore the science and learn more about our R&D](https://www.insight-rx.com/data-science?hsLang=en)
- [Scientific Publications Impactful research manuscripts with at least one InsightRX author](https://www.insight-rx.com/data-science/scientific-publications?hsLang=en)
- [How to Cite Using one of our apps? Follow this easy guide for citation in research](https://www.insight-rx.com/how-to-cite-insightrx-nova?hsLang=en)
- Explore
- [Success Stories Case studies from real InsightRX customers about their journey](https://www.insight-rx.com/success-stories?hsLang=en)
- [White Papers In-depth analysis and best practices for review and download](https://blog.insight-rx.com/resources/tag/white-papers?hsLang=en)
- [Pubs. Using InsightRX Review research that has used InsightRX applications](https://www.insight-rx.com/publications-using-insightrx-software?hsLang=en)
- [Blog](https://blog.insight-rx.com/resources?hsLang=en)
- [All Blog Posts Read the latest posts by our team of experts](https://blog.insight-rx.com/resources?hsLang=en)
- [Product Innovation The latest updates on our products, services, and science](https://blog.insight-rx.com/resources?section=product_innovation&hsLang=en)
- [Thought Leadership Posts from our team of experts on PK, MIPD, science, and more](https://blog.insight-rx.com/resources?section=thought_leadership&hsLang=en)
- Company
- About
- [About Us Our story, what drives us and why we're passionate about our work](https://www.insight-rx.com/about?hsLang=en)
- [Leadership Founders and team leaders who strive toward excellence in MIPD](https://www.insight-rx.com/leadership?hsLang=en)
- [Advisory Board Scientists and experts to ensure our collective success](https://www.insight-rx.com/advisory-board?hsLang=en)
- [Careers Interested in joining? View available openings here](https://www.insight-rx.com/careers?hsLang=en)
- [Customers Hear what others have to say about their experience](https://www.insight-rx.com/customers?hsLang=en)
- Press
- [All Stories InsightRX news, company updates, and more](https://blog.insight-rx.com/press-releases?hsLang=en)
- [Press Releases Announcements for events, partnerships, and company updates](https://blog.insight-rx.com/press-releases?section=press_releases&hsLang=en)
- [Media InsightRX in the news — digital, print, podcasts, and other outlets](https://blog.insight-rx.com/press-releases?section=media&hsLang=en)
[](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574)
[](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=AVxigLIVhNAV4frdGw7WK4%2FsUL9BSW7sTFfaUWeB6c0miW6Ak22RBUNE5R8BeaQrWqzDSork53FkrNEqiSn%2FTM4f%2BVzPNcA0Ikxp7y6GqZRUQJ2HulFNF849cXXSebQBDVQXFR3hVvn8tZ3jkxYoygqRgjFUwIOapgI0FM8UFCm2xhxz2SgLhEGqk1U%3D&webInteractiveContentId=193831493462&portalId=40041574)
Beta-Lactams
# Precision dosing for beta-lactam therapy.
Beta-lactams are first-line for most serious infections, yet a standard dose leaves many acutely ill patients below their pharmacodynamic target. These modules support individualized dosing for the agents where reaching that target matters most.
InsightRX helps clinicians dose beta-lactams in line with the 2026 multisociety consensus guidance, endorsed by IDSA, ACCP, SCCM, and ESCMID, on dose individualization in acutely ill patients. [Read more below.](https://www.insight-rx.com/provider/drug-modules/beta-lactam#barreto-2026)
1. [Home](https://www.insight-rx.com?hsLang=en)
2. [MIPD for Providers](https://www.insight-rx.com/provider?hsLang=en)
3. [Drug Modules for Provider MIPD Applications](https://www.insight-rx.com/provider/drug-modules?hsLang=en)
4. Beta-lactam
## The problem: why a standard dose is not a reliable dose
Most beta-lactam dosing still relies on a one-size-fits-all approach, scaled to body weight or estimated kidney function. In acutely ill patients, that breaks down. Critical illness alters the two pharmacokinetic parameters that matter most, the clearance (CL) and the volume of distribution (Vd) of these drugs, through many overlapping mechanisms at once.
This variability is why individualized dosing is gaining formal support. In one prospective study of critically ill patients, a model-based dosing tool demonstrated a dose different from the standard label in roughly one in five cases ([Heil et al., 2018](https://doi.org/10.1128/AAC.01008-18)).
And in 2026, a multisociety consensus guidance endorsed by IDSA, ACCP, SCCM, and ESCMID suggested beta-lactam dose individualization to improve patient-centered outcomes, citing a meta-analysis in which it was associated with nearly twice the odds of clinical cure.
Predominant PK effect shown. Most populations affect both to some degree.
Augmented renal clearance
Fast elimination drives concentrations below target.
CL
Renal replacement therapy
Extracorporeal circuits change drug removal.
CL
Kidney dysfunction
Slowed elimination risks accumulation.
CL
Sepsis & septic shock
Capillary leak expands the distribution space.
Vd
Extremes of body weight
Body habitus shifts the volume of distribution.
Vd
Hypoalbuminemia
A higher unbound fraction shifts both parameters.
CLVd
## The solution: Bayesian MIPD
A dosing table sorts patients into bands. It asks whether estimated kidney function sits above or below a threshold and applies the same regimen to everyone on the same side of the line. It cannot ask where inside that band a particular patient falls, or what exposure that patient will actually reach.
### Which regimen would you choose?
Against an organism at an MIC of 8 mg/L, the useful cefepime trough is narrow at both ends. The 2026 consensus guidance sets a minimum target of 100% *f*T\>MIC, which means holding the trough at or above the MIC, and notes that cefepime neurotoxicity risk rises at troughs above 20–35 mg/L ([Barreto et al., Pharmacotherapy, 2026](https://doi.org/10.1002/phar.70181)). Taking the cautious end of that range leaves a window of roughly 8–20 mg/L, about 2.5-fold, and a dosing table has no way to aim at it.
72-year-old female
Weight
55 kg
Serum creatinine
0.6 mg/dL
Estimated CrCl
74 mL/min
Target trough
8–20 mg/L
Hospital-acquired pneumonia, day 2. *Pseudomonas aeruginosa*, cefepime MIC 8 mg/L. No prior kidney disease. Frail, low muscle mass.
Select a regimen
Every regimen gives the first dose over 30 minutes, then maintenance as a 3-hour infusion; four doses shown. Illustrative simulation only.
Select a regimen to see the exposure this patient would be estimated to reach.
### What a dosing table cannot see
The patient's estimated clearance is 74 mL/min. Most hospital nomograms begin adjusting at 60, so the patient is never flagged for a reduction at all. The estimate is not wrong, only too coarse to say where inside that band a 55 kg, 72-year-old patient will land.
Model-informed precision dosing runs before the first dose. MIPD platforms like InsightRX Nova read age, weight, sex and creatinine together, in the continuous relationships those covariates actually hold, and project what each candidate regimen would produce for this patient rather than for a generic patient's band.
Where each trough is predicted to land
## Module bundle features and benefits
Modules included in this bundle
- Cefepime
- Meropenem
- Piperacillin
- Piperacillin-tazobactam
- Amoxicillin
- Ceftriaxone
- Ceftazidime
Each module runs on population PK models reviewed and validated by experts in data science and pharmacometrics before deployment.
Infusion strategy support
Model intermittent, extended, and continuous infusions to keep free concentrations above the MIC across the interval.
Reach clinical targets from the beginning
Start from a model-based estimate of each patient's exposure, giving clinical teams the tools to assess target early rather than after days of adjustment.
Stewardship program analytics
Apollo helps teams track beta-lactam target attainment across antimicrobial stewardship programs, giving a clear view of performance and where to focus.
Adapt to shifting physiology
Account for the fast-clearing, fluid-shifted physiology of acutely ill patients that standard dosing misses.
## The platform behind every module
InsightRX Nova delivers Bayesian model-informed dosing at the point of care; InsightRX Apollo provides program-level analytics to track target attainment and outcomes; and patented Continuous Learning keeps the underlying models accurate as real-world data accrues.
### [Bayesian MIPD InsightRX Nova Individualize every dose using validated pharmacokinetic models and real-time patient data, helping clinicians reach therapeutic targets faster.](https://www.insight-rx.com/provider/nova?hsLang=en)
### [Clinical Analytics InsightRX Apollo Monitor drug performance, track program outcomes, and surface clinical trends across your health system in real time.](https://www.insight-rx.com/provider/apollo?hsLang=en)
### [Ongoing Improvement Continuous Learning Models retrain on real-world outcomes data, improving accuracy over time with no action required from clinical or IT teams.](https://www.insight-rx.com/platform/continuous-learning?hsLang=en)
## A multisociety consensus on individualized dosing
In 2026, seven professional societies published consensus guidance on beta-lactam dose individualization in acutely ill patients ([Barreto et al., Pharmacotherapy, 2026](https://doi.org/10.1002/phar.70181)). In the panel's meta-analysis, dose regimen individualization was associated with nearly twice the odds of clinical cure (odds ratio 1.99, 95% CI 1.54 to 2.56).
### On patient populations:
The guidance identifies the acutely ill populations where individualization matters most. Unstable pharmacokinetics is the common thread: critical illness, organ support, and shifting kidney function all pull drug concentrations away from what a standard dose predicts.
Section 3.5.1
The panel supports the use of beta-lactam dose individualization in patients with critical illness (e.g., intensive care unit, sepsis, septic shock), use of extracorporeal devices including extracorporeal membrane oxygenation, kidney replacement therapy, plasmapheresis, and blood purification/adsorptive systems (e.g., hemoadsorption) and/or in patients with kidney dysfunction (e.g., acute kidney injury, chronic kidney disease) or augmented renal clearance.
### On implementation:
Many health systems already run Bayesian dosing programs for vancomycin. The panel supports building beta-lactam programs the same way, with iterative evaluation once a program is in place.
Section 4.2.1
The panel supports patterning beta-lactam dose individualization workflows after those of other antibiotics such as vancomycin.
### On methodology:
The panel draws a clear distinction on method. Proactive model-informed precision dosing anticipates a patient's exposure from the first dose rather than reacting to a level after the fact, and the guidance favors it over traditional therapeutic drug monitoring.
Section 5.1.1
The panel supports the use of proactive MIPD with beta-lactam concentrations over traditional TDM, the latter of which is reactive.
These statements are drawn from the 2026 multisociety consensus guidance. [Read the full guidance in Pharmacotherapy](https://doi.org/10.1002/phar.70181).
Maximize therapeutic success
with precision medicine.
[](https://cta-service-cms2.hubspot.com/web-interactives/public/v1/track/redirect?encryptedPayload=…)
#### What We Do
##### For Providers
- [Nova (Bayesian Dosing)](https://www.insight-rx.com/provider/nova?hsLang=en)
- [Apollo (Clinical Analytics)](https://www.insight-rx.com/provider/apollo?hsLang=en)
- [Drug Modules](https://www.insight-rx.com/provider/drug-modules?hsLang=en)
##### For Life Sciences
- [Nova (MIPD for Clinical Trials)](https://www.insight-rx.com/life-sciences/nova?hsLang=en)
- [Astra (AI-Powered Clin Pharm)](https://www.insight-rx.com/life-sciences/astra?hsLang=en)
- [Companion Applications](https://www.insight-rx.com/life-sciences/nova?hsLang=en#companion-applications)
#### How We Do It
##### Platform
- [Continuous Learning](https://www.insight-rx.com/platform/continuous-learning?hsLang=en)
- [Integrations](https://www.insight-rx.com/platform/integrations?hsLang=en)
- [Security & Regulatory](https://www.insight-rx.com/platform/security-regulatory?hsLang=en)
- [Success & Support](https://www.insight-rx.com/platform/success-support?hsLang=en)
##### Science
- [Data Science](https://www.insight-rx.com/data-science?hsLang=en)
- [Scientific Publications](https://www.insight-rx.com/data-science/scientific-publications?hsLang=en)
#### Information
##### Resources
- [Success Stories](https://www.insight-rx.com/success-stories?hsLang=en)
- [White Papers](https://www.insight-rx.com/white-papers?hsLang=en)
- [Publications Using InsightRX](https://www.insight-rx.com/publications-using-insightrx-software?hsLang=en)
- [How to Cite InsightRX](https://www.insight-rx.com/how-to-cite-insightrx-nova?hsLang=en)
##### Blog
- [All Posts](https://blog.insight-rx.com/resources?hsLang=en)
- [Product Innovation](https://blog.insight-rx.com/resources?section=product_innovation&hsLang=en)
- [Thought Leadership](https://blog.insight-rx.com/resources?section=thought_leadership&hsLang=en)
#### About
- [Our Story](https://www.insight-rx.com/about?hsLang=en)
- [Leadership](https://www.insight-rx.com/leadership?hsLang=en)
- [Advisory Board](https://www.insight-rx.com/advisory-board?hsLang=en)
- [Our Customers](https://www.insight-rx.com/customers?hsLang=en)
- [Press Releases](https://blog.insight-rx.com/press-releases?section=press_releases&hsLang=en)
- [Media](https://blog.insight-rx.com/press-releases?section=media&hsLang=en)
- [Careers](https://www.insight-rx.com/careers?hsLang=en)
- [Contact](https://www.insight-rx.com/contact-us?hsLang=en)
---
InsightRX Nova is HITRUST CSF r2 certified, CE marked, and 21 CFR Part 11 compliant. Our quality management, risk management, software lifecycle, and usability engineering processes conform to ISO 13485, IEC 62304, ISO 14971, IEC 62366-1, and IEC 82304-1.
InsightRX Nova is not considered to be a medical device in the U.S. and has not been submitted to the U.S. Food and Drug Administration for review or clearance.
740-05000-REC-01 · 08/2025
---
[](https://www.insight-rx.com/?hsLang=en)
548 Market Street
#88083
San Francisco, CA 94104
---
© 2026 InsightRX, Inc. All rights reserved.
[Privacy Policy](https://www.insight-rx.com/privacy-policy?hsLang=en) Cookie Preferences
```json
{
"@context" : "https://schema.org",
"@type" : "BreadcrumbList",
"itemListElement" : [ {
"@type" : "ListItem",
"item" : {
"@id" : "https://www.insight-rx.com"
},
"name" : "Home",
"position" : 1
}, {
"@type" : "ListItem",
"item" : {
"@id" : "https://www.insight-rx.com/provider"
},
"name" : "MIPD for Providers",
"position" : 2
}, {
"@type" : "ListItem",
"item" : {
"@id" : "https://www.insight-rx.com/provider/drug-modules"
},
"name" : "Drug Modules for Provider MIPD Applications",
"position" : 3
}, {
"@type" : "ListItem",
"item" : {
"@id" : "https://www.insight-rx.com/provider/drug-modules/beta-lactam"
},
"name" : "Beta-lactam",
"position" : 4
} ]
}
```